Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 17, 2009

View Archived Issues

Yonsei University scientists disclose novel oncolytic compounds

Entecavir exhibits superior antiviral activity to adefovir in CHB patients

Vicriviroc exhibits long-term safety in phase II HIV trials, phase III trials under way

PEG-Interferon lambda effective in HCV genotype 1 relapsed patients

Taribavirin has anemia benefits versus ribavirin in HCV patients

IMO-2125 shows promising anti-HCV activity in preclinical evaluation

New vanilloid TRPV1 receptor ligands claimed by sanofi-aventis as analgesics

Protein kinase inhibitors in development at IRM for the treatment of cancer

Novel antiparkinsonian compounds described by Israeli scientists

Spherix reports interim results of phase III trial of D-tagatose in diabetes

FDA approves Lysteda for the treatment of menorrhagia

Alkermes reports results from phase III naltrexone trial for opioid dependence

Aegerion reports additional lomitapide phase III data

Winston Laboratories reports topline results of phase II civamide patch trial

Esperion Therapeutics initiates phase I ETC-1002 trial in healthy volunteers

Genzyme receives FDA complete response letter on Lumizyme marketing application

Eisai launches Lusedra injection for monitored anesthesia care sedation

Seattle Genetics initiates phase I SGN-75 trial in patients with cancer

Poniard's phase III trial of picoplatin in lung cancer does not meet primary endpoint

Brookstone Pharmaceuticals becomes Acella Pharmaceuticals

Onyx acquires Proteolix

Sciele Pharma to acquire Addrenex

SB-939 shows favorable PK, PD and safety in phase I trial in advanced solid tumors

COMP recommends orphan drug status for Proteo's Elafin in esophagus carcinoma

GSK and Nabi sign option and licensing agreement for NicVAX nicotine vaccine